Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: On a miserable day for the markets, Regeneron Pharmaceuticals
So what: According to a just-released Food and Drug Administration report, the company's new VEGF Trap-Eye drug, for treatment of "wet age-related macular degeneration," a leading cause of blindness, is just as good as Roche's Lucentis, which is already on the market.
Now what: "Just as good?" It sounds like the FDA is damning Regeneron with faint praise, but the key takeaway here is that the FDA looks inclined to approve the drug for sale. If it does that, analysts think Regeneron could steal market share from Roche, inasmuch as Trap-Eye can be administered as infrequently as once every two months, versus the once-a-month regimen for Lucentis.
With a $1.5 billion market at stake (triple the size of Regeneron's current revenue stream), that's better than a stick in the eye.
Can Regeneron parlay this news into an actual profit? Add it to your Watchlist and find out.Fool contributor Rich Smith does not own (or short) either company named above. The Motley Fool has a disclosure policy. Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
More from The Motley Fool
Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?
An immuno-oncology drug that's in the works could generate significant revenue growth someday.
This Double Whammy Caused Regeneron Pharmaceuticals Inc. to Fall 10% in November
Shareholders aren't seeing too clearly after this double-dose of news concerning lead drug Eylea.
Here's Why Regeneron Pharmaceuticals Inc. Slipped 10% in October
Tiny start-up AnaptysBio helped spread fear that Dupixent's ongoing commercial launch might fizzle out.